Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Grifols S.A. (GRFS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,642,743
  • Shares Outstanding, K 682,820
  • Annual Sales, $ 4,881 M
  • Annual Income, $ 749,050 K
  • 36-Month Beta 1.19
  • Price/Sales 2.90
  • Price/Cash Flow 14.36
  • Price/Book 3.00

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 0.31
  • Number of Estimates 2
  • High Estimate 0.32
  • Low Estimate 0.30
  • Prior Year 0.29
  • Growth Rate Est. (year over year) +6.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.94 +2.11%
on 08/15/18
21.79 -6.56%
on 07/27/18
-1.10 (-5.13%)
since 07/16/18
3-Month
19.94 +2.11%
on 08/15/18
24.97 -18.46%
on 06/13/18
-2.37 (-10.43%)
since 05/16/18
52-Week
19.94 +2.11%
on 08/15/18
25.18 -19.14%
on 01/23/18
-0.13 (-0.63%)
since 08/16/17

Most Recent Stories

More News
Grifols Achieves Key Milestone with FDA Approval of the New Consolidated Manufacturing Facility (CMF) for Production of Recombinant Proteins

Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a global healthcare company with a history of more than 75 years of improving people's health and well-being and a leader in the development of innovative...

GRFS : 20.37 (+1.95%)
GRF : 7.91 (+0.83%)
Procleix® Zika Virus Assay Approved by the FDA for Blood Screening on the Procleix® Panther® System

Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, today announced that the U.S....

GRFS : 20.37 (+1.95%)
GRF : 7.91 (+0.83%)
Free Technical Research on ImmunoGen and Three More Biotech Equities

Stock Research Monitor: GRFS, HALO, and IMUC

IMUC : 0.21 (unch)
GRFS : 20.37 (+1.95%)
HALO : 17.09 (-0.52%)
Grifols Expands its NAT Solutions Portfolio with New FDA Approvals for Two Assays

Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, announced today that it has received...

GRFS : 20.37 (+1.95%)
GRF : 7.91 (+0.83%)
Factors of Influence in 2018, Key Indicators and Opportunity within Eldorado Gold, Lamar Advertising, Bitauto, Magellan Midstream Partners, Deutsche Bank Aktiengesellschaft, and Grifols, S.A. -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Eldorado Gold Corporation (NYSE:EGO),...

MMP : 70.22 (+0.53%)
LAMR : 75.74 (+0.52%)
GRFS : 20.37 (+1.95%)
BITA : 20.22 (+0.50%)
EGO : 0.93 (-0.58%)
DB : 11.23 (+0.36%)
Grifols Launches a New Testing Service for Patients Treated with Daratumumab

Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), one of the leading companies in the world in plasma-derived biological medicines and transfusion medicine, today announced it is adding a Daratumumab neutralization...

GRFS : 20.37 (+1.95%)
GRF : 7.91 (+0.83%)
Grifols Expands its Blood Typing Solutions Portfolio in the United States with Antisera Reagents

Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, today announced the expansion...

GRFS : 20.37 (+1.95%)
GRF : 7.91 (+0.83%)
Report: Exploring Fundamental Drivers Behind Itau Unibanco Holding S.A, Weibo, Redhill Biopharma, Shenandoah Telecommunications, Grifols, S.A, and Orthofix International N.V -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Itau Unibanco Holding S.A....

RDHL : 6.10 (+0.83%)
OFIX : 53.44 (+0.38%)
SHEN : 37.20 (+2.06%)
GRFS : 20.37 (+1.95%)
ITUB : 11.31 (+0.09%)
WB : 74.09 (+1.79%)
Grifols 2017 Annual Report on Form 20-F filed with the SEC on April 6, 2018

Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) announced that it has filed its 2017 Annual Report on Form 20-F with the United States Securities and Exchange Commission ("SEC") on April...

GRFS : 20.37 (+1.95%)
GRF : 7.91 (+0.83%)
Consolidated Research: 2018 Summary Expectations for B Communications, Student Transportation, Aurinia Pharmaceuticals, Grifols, S.A., NEXEO SOLUTIONS, and ASML Holding N.V. -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of B Communications Ltd. (NASDAQ:BCOM),...

BCOM : 6.64 (+1.53%)
STB : 7.50 (unch)
NXEO : 10.11 (+2.95%)
AUPH : 5.45 (+0.18%)
NXEOU : 11.45 (+5.82%)
GRFS : 20.37 (+1.95%)
ASML : 197.73 (+0.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade GRFS with:

Business Summary

Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience...

See More

Key Turning Points

2nd Resistance Point 20.38
1st Resistance Point 20.18
Last Price 20.37
1st Support Level 19.86
2nd Support Level 19.74

See More

52-Week High 25.18
Fibonacci 61.8% 23.18
Fibonacci 50% 22.56
Fibonacci 38.2% 21.94
Last Price 20.37
52-Week Low 19.94

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar